Dissemin is shutting down on January 1st, 2025

Published in

BioMed Central, Clinical and Molecular Allergy, 1(13), 2015

DOI: 10.1186/s12948-015-0025-9

Links

Tools

Export citation

Search in Google Scholar

Rituximab in refractory sarcoidosis: a single centre experience

Journal article published in 2015 by Francesco Cinetto, Nicolò Compagno, Riccardo Scarpa ORCID, Giacomo Malipiero, Carlo Agostini
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature.